TAP
GILD icon

TSG Advice Partners’s Gilead Sciences GILD Stock Holding History

TSG Advice Partners’s Portfolio GILD Stock Details GILD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$856K Buy
6,145
+4,508
+275% +$631K 0.13% 57
2025
Q4 		$201K Buy
+1,637
New +$199K 0.03% 115

Other funds holding GILD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

TSG Advice Partners's GILD Position: Q1 2026 in Review

TSG Advice Partners increased its Gilead Sciences (GILD) stake by 275% in Q1 2026, buying an estimated $631K and bringing the position to 6,145 shares worth $856K. The position accounts for 0.13% of the portfolio, ranked #57.

TSG Advice Partners first reported a position in GILD in Q4 2025 and has held it in 2 quarters since. 2,320 funds tracked by Wall St. Rank hold GILD as of Q1 2026.

  • TSG Advice Partners held 6,145 shares of Gilead Sciences worth $856K as of Q1 2026.
  • TSG Advice Partners bought 4,508 Gilead Sciences shares in Q1 2026, an estimated $631K.
  • Gilead Sciences made up 0.13% of TSG Advice Partners's portfolio in Q1 2026, its #57 holding.
  • TSG Advice Partners first reported a position in Gilead Sciences in Q4 2025 and has held it in 2 quarters since.
  • 2,320 funds tracked by Wall St. Rank held Gilead Sciences as of Q1 2026.

Based on TSG Advice Partners's 13F filing for Q1 2026, filed 24 Apr 2026.